心房颤动的抗凝治疗:CHA_(2)DS_(2)-VASc评分之外

Anticoagulant Therapy for Atrial Fibrillation:Beyond CHA_(2)DS_(2)-VASc Score

目前心房颤动抗凝治疗评估主要依靠CHA_(2)DS_(2)-VASc评分,但CHA_(2)DS_(2)-VASc评分的特异性较低,需识别出能真正从抗凝治疗中获益的患者。近年来对生物标志物、心房颤动患者卒中危险因素及评价模型的研究不断涌现。现从心房颤动及心房颤动射频消融术后长期抗凝治疗的角度,针对目前除CHA_(2)DS_(2)-VASc评分以外的卒中危险因素及评分系统进行总结,为抗凝治疗策略的探索提供参考。

At present,the evaluation of anticoagulant therapy for atrial fibrillation mainly depends on CHA_(2)DS_(2)-VASc score.However,the specificity of CHA_(2)DS_(2)-VASc score is low,so it is necessary to identify patients who can really benefit from anticoagulant therapy.In recent years,studies on biomarkers,stroke risk factors and evaluation models in atrial fibrillation patients have been emerging.From the perspective of long-term anticoagulant therapy after radiofrequency ablation in atrial fibrillation patients,this paper summarizes the current stroke risk factors and scoring system other than CHA_(2)DS_(2)-VASc score,so as to provide reference for the exploration of anticoagulant therapy strategy.